DREAMM-9: PHASE I STUDY OF BELANTAMAB MAFODOTIN (BELAMAF) PLUS STANDARD OF CARE (SOC) IN PATIENTS WITH TRANSPLANT-INELIGIBLE NEWLY DIAGNOSED MULTIPLE MYELOMA (TI-NDMM)

Updated progression-free survival (PFS) and depth of response in IKEMA, a randomized Phase 3 trial of isatuximab, carfilzomib and dexamethasone (Isa-Kd) vs Kd in relapsed multiple myeloma (MM)

CILTACABTAGENE AUTOLEUCEL (CILTA-CEL), A B-CELL MATURATION ANTIGEN (BCMA)-DIRECTED CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY, IN PATIENTS (PTS) WITH MULTIPLE MYELOMA (MM) AND EARLY RELAPSE AFTER INITIAL THERAPY: CARTITUDE-2 COHORT B

EFFICACY AND SAFETY OF CILTACABTAGENE AUTOLEUCEL (CILTA-CEL) IN LENALIDOMIDE-REFRACTORY PATIENTS (PTS) WITH PROGRESSIVE MULTIPLE MYELOMA (MM) AFTER 1–3 PRIOR LINES OF THERAPY (LOT): CARTITUDE-2 UPDATED RESULTS

POOLED ANALYSIS OF PROGRESSION-FREE SURVIVAL (PFS) ACCORDING TO CYTOGENETIC ABNORMALITY (CA) STATUS IN PATIENTS WITH MULTIPLE MYELOMA (MM) TREATED WITH IXAZOMIB- VS PLACEBO-BASED THERAPY IN THE TOURMALINE PHASE 3 STUDIES

AN ONGOING PHASE I STUDY SHOWS CLINICALLY MEANINGFUL ACTIVITY AND MANAGEABLE SAFETY OF CEVOSTAMAB MONOTHERAPY IN PATIENTS WITH HEAVILY PRE-TREATED RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM) [ENCORE]

EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CYTOKINE RELEASE SYNDROME WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA

UPDATE FROM A FIRST-IN-HUMAN PHASE 1 STUDY OF MODAKAFUSP ALFA (TAK-573), A FIRST-INCLASS IMMUNOCYTOKINE, IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM)